Skip to main content
padlock icon - secure page this page is secure

Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura

Buy Article:

$59.00 + tax (Refund Policy)


The management of patients with refractory immune thrombocytopenic purpura (ITP) may be difficult. We describe a rapid-onset very long-term remission (9 years) induced by short-term rituximab monotherapy in a 62-year-old man with treatment-refractory chronic ITP. Over a 30-year period from the original diagnosis to last follow-up, the patient needed renewed treatment twelve times within the first two decades and was subsequently brought in continuous complete remission for the last decade by a single course of rituximab. The effect of rituximab in ITP has previously been described. However, in chronic, treatment-refractory ITP occurring in elderly patients, remission rates tend to be low and of short duration.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: chronic immune thrombocytopenic purpura; immune thrombocytopenic purpura; rituximab

Document Type: Research Article

Affiliations: 1: Department of Hematology, Aarhus University Hospital, Aarhus 2: Department of Medicine, Randers County Hospital, Randers, Denmark

Publication date: March 1, 2011

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more